On January 24, Alvotech and Bioventure, a subsidiary of GlobalOne Healthcare Holding LLC, announced that the Saudi Food & Drug Authority has approved SIMLANDI, a biosimilar referencing HUMIRA (adalimumab), in Saudi Arabia. According to the press release, Bioventure is Alvotech's exclusive strategic partner for the commercialization of SIMLANDI in the Middle East and North Africa and will be responsible for commercialization of the biosimilar. As we've previously reported, the same biosimilar has been approved in Canada as SIMLANDI; in the EU, Norway, Iceland, Lichtenstein, the UK, Switzerland as HUKYNDRA; and in Australia as CIPTUNEC/ARDALICIP.
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.
We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.